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ABSTRACT
Background. The role of radiation therapy (RT) is unclear
for metaplastic breast cancer (MBC). We hypothesized that
RT would improve overall survival (OS) and disease-spe-
cific survival (DSS).
Materials and Methods. We used the Surveillance, Epi-
demiology, and End Results (SEER) database to identify
MBC patients diagnosed from1988 to 2006. Univariate
analyses of patient, tumor, and treatment-specific factors
on OS and DSS were performed using the Kaplan–Meier
method and differences among survival curves assessed via
log rank. Variables assessed included patient age, race/
ethnicity, histologic subtype, tumor grade, T stage, N stage,
M stage, hormone receptor status, surgery type, and use of
RT. Cox proportional hazards models used all univariate
covariates. Risks of mortality were reported as hazard
ratios (HR) with 95% confidence intervals (95% CI); sig-
nificance was set at P B 0.05.
Results. Among 1501 patients, RT was given to 580
(38.6%). Ten-year OS and DSS were 53.2, and 68.3%,
respectively. In the overall analysis, RT provided an OS
(HR 0.64; 95% CI, 0.51–0.82; P \ 0.001) and DSS (HR
0.74; CI, 0.56–0.96; P \ 0.03) benefit. When patients were
stratified according to type of surgery, RT provided an OS
but not a DSS benefit to lumpectomy (HR 0.51; CI, 0.32–
0.79, P \ 0.01) and mastectomy patients (HR 0.67; CI,
0.49–0.90; P \ 0.01).
Conclusions. Our findings support the use of RT for
patients with MBC following lumpectomy or mastectomy.
These retrospective findings should be confirmed in a
prospective clinical trial.
Metaplastic breast cancer (MBC) is characterized by the
histologic presence of 2 or more cellular types commonly
representing a mixture of epithelial and mesenchymal
components.1–6 MBC represents 0.25–1% of breast cancers
diagnosed annually.1,7,8 The prognosis of and optimal
treatment for MBC are largely unknown. Review of more
than 800 MBC patients in the National Cancer Database
from 2001 to 2003 indicates that, compared with patients
with invasive ductal carcinoma (IDC), those with MBC
have larger, higher-grade and more hormone receptor
negative tumors with less involvement of regional lymph
nodes.8 Overall, more than 70% of patients with MBC
present with American Joint Committee on Cancer (AJCC)
stage II or greater disease, compared with approximately
50% of patients with IDC.8
The World Health Organization (WHO) recognized
MBC as a unique pathologic entity in 2000. Since then, the
incidence of MBC has increased, presumably because of
increased recognition by pathologists.8,9 Management of
MBC has largely paralleled that of IDC. Compared with
patients with IDC, however, those with MBC have worse
outcomes with 5-year survival rates ranging from 49 to
68%.1,10,11
Information regarding the role of adjuvant radiation
therapy (RT) for the treatment of MBC is sparse.12,13 The
Breast Disease Site Team reported that only 42.5% of their
MBC patients received RT compared with 52.0% of IDC
patients, but outcome data were not reported.8 Given the
aggressive features of MBC relative to IDC and the dearth
of information concerning the role of RT, we sought to use
a large, population-based cancer registry to analyze the
effects of RT on overall (OS) and disease-specific survival
(DSS) in patients with MBC.
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METHODS
The Surveillance, Epidemiology, and End Results
(SEER) database of the National Cancer Institute was used
to identify all patients with MBC diagnosed from 1988 to
2006. SEER collects cancer incidence and survival data
from 17 population-based cancer registries representing
26% of the U.S. population.
All cases of primary, histologically confirmed, MBC
were eligible. We used SEER ICD-0-3 codes 8560, 8562,
8570–8572, 8575, and 8980–8982. Patients identified by
death certificate or autopsy, and those with missing cause
of death were excluded. The final sample included 1501
patients.
Survival time was calculated as the number of completed
months between the date of diagnosis and whichever
occurred first: date of death, date last known to be alive, or
December 31, 2006. The endpoints for the present study were
OS and DSS. For calculations of OS and DSS, patients who
were lost to follow-up or survived beyond December 31,
2006 were coded as censored observations. Similarly, for
calculations of DSS, patients who died from non-breast-
related causes were coded as censored observations.
We compared univariate rates of OS and DSS according
to use of RT using the Kaplan–Meier method. We further
stratified patients by surgery type: lumpectomy versus
mastectomy. Additional univariate survival comparisons
were made for the following patient, tumor, and treatment-
specific factors: age at diagnosis, race/ethnicity, histologic
subtype, tumor grade, T stage (tumor size in cm), N stage
(number of positive lymph nodes), M stage (presence of
distant metastasis), hormone receptor status, type of pri-
mary surgery (lumpectomy or mastectomy), and use of RT
(radiation, no radiation, unknown). Differences between or
among survival curves were assessed via the log-rank test.
Cox proportional hazards models assessed the effect of
RT on OS and DSS. All univariate factors were included in
the multivariate model. For purposes of further evaluation
of the effect of RT, we stratified patients according
to whether they received lumpectomy or mastectomy as
primary surgical treatment and performed subgroup
multivariate analyses. Unknown or missing data were
presented and analyzed concomitantly.
To examine whether the breast cancers described prior
to recognition of MBC as a distinct pathologic entity by the
WHO in 2000 were similar to those diagnosed after WHO
recognition, patients were divided into 2 eras. Those
diagnosed with MBC in 2000 or earlier were placed in era
I, while those diagnosed from 2001 to 2006 were placed in
era II. Univariate and multivariate analyses compared
patients from the 2 treatment eras.
Risks of overall and disease-specific mortality were
reported as hazard ratios (HR) with 95% confidence
intervals (95% CI); significance was set at P B 0.05. All
statistical analyses were two-tailed and performed using
STATA version 10 (StataCorp, College Station, TX) or
SPSS (SPSS, Inc., Chicago, IL).
This study was exempt from institutional review board
(IRB) review.
RESULTS
Entry criteria were met by 1501 patients. Characteristics
of the study population are presented in Table 1. Briefly,
the majority of patients were white (73.0%) women
(99.9%). Multiple histologic subtypes were represented.
Prevalent histologies included: metaplastic not otherwise
specified (57.3%), adenosquamous carcinoma (18.1%), and
carcinosarcoma (11.7%). Only 3.9% of patients had an
unknown T stage, while 68.7% had tumors greater than
2 cm in diameter (T2, T3, or T4 tumors). Nodal status was
unknown for 15.3%; 22.5% were node positive. A majority
of patients presented without evidence of distant metasta-
ses (92.5%). MBC tumors were most commonly of higher
grade (67.8%), although 20.2% had unknown tumor grade.
Estrogen receptor and progesterone receptor status was
negative in 69.2 and 69.9%, respectively. Estrogen receptor
status was unknown for 17.8%, and progesterone receptor
status was unknown for 18.5%. Patients were most com-
monly treated with mastectomy (55.5%); 41.0% of patients
received lumpectomy while 2.9% did not undergo poten-
tially curative surgery. Patients with T3 or T4 tumors were
more likely to receive mastectomy (83.4%) than were
patients with smaller tumors (46.5%). Similarly, 74.3% of
node-positive patients received mastectomy. Radiation
therapy was administered to 38.6% of patients; 23.4% of
mastectomy patients and 61.8% of lumpectomy patients
received RT.
Overall survival of the entire cohort was 63.3% at
5 years and 53.2% at 10 years. Disease-specific survival of
the cohort was 71.8% at 5 years and 68.3% at 10 years. In
patients receiving RT, OS was 73.2% at 5 years and 60.3%
at 10 years versus 56.9 and 48.3% in patients not receiving
RT (Fig. 1a). DSS for patients receiving RT was 75.9% at
5 years and 71.7% at 10 years compared with 69.0 and
66.1% in patients not receiving RT (Fig. 1b).
Patients receiving lumpectomy and RT demonstrated
superior OS and DSS to similar patients not receiving RT
(P \ 0.001 and P = 0.003, respectively) on univariate
analysis. OS for patients receiving lumpectomy and RT
was 65.5% at 10 years, while OS for those not receiving
RT was 59.3% (Fig. 2a). DSS for patients receiving
lumpectomy and RT was 79.4% at 10 years while DSS for
those not receiving RT was 70.7% (Fig. 2b). Conversely,
on univariate analysis, patients treated with mastectomy
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and RT did not demonstrate OS or DSS benefits compared
with their counterparts who did not receive RT (P = 0.49
and P = 0.22, respectively). The 10-year OS rate for
mastectomy patients receiving RT was 47.7 and 45.3% in
patients not receiving RT (Fig. 3a). The 10-year DSS rate
for mastectomy patients receiving RT was 55.0 and 65.3%
in patients not receiving RT (Fig. 3b).
Factors influencing OS on univariate analysis included
histologic subtype (P = 0.002), tumor grade (P \ 0.001),
T stage (P \ 0.001), N stage (P \ 0.001), M stage (P \
0.001), surgery type (P \ 0.001), and RT (P \ 0.001).
Univariate factors influencing DSS included race/ethnicity
(P = 0.03), histologic subtype (P = 0.04), tumor grade
(P \ 0.001), T stage (P \ 0.001), N stage (P \ 0.001), M
stage (P \ 0.001), surgery type (P \ 0.001), and RT (P \
0.01).
Results of the entire cohort multivariate analysis for OS
are presented in Table 2A. Factors increasing the risk of
death due to any cause included increasing age (HR 1.02,
95% CI 1.02–1.03; P \ 0.01), carcinosarcoma histology
(HR 1.52, 95% CI 1.13–2.04; P = 0.005), T3 (HR 2.82,
95% CI 2.12–3.75; P \ 0.01) and T4 tumors (HR 1.95,
95% CI 1.45–2.61; P \ 0.01), N1 status (HR 2.40, 95% CI
1.83–3.15; P \ 0.01), N2 status (HR 2.71, 95% CI 1.83–
4.02; P \ 0.01), N3 status (HR 1.92, 95% CI 1.11–3.33;
P = 0.02), unknown nodal status (HR 2.32, 95% CI 1.76–
3.06; P \ 0.01), and distant metastases (HR 4.73, 95% CI
3.51–6.39; P \ 0.01). Factors decreasing the risk of death
due to any cause included T1 tumors (HR 0.68, 95% CI
0.50–0.93; P \ 0.01) and use of RT (HR 0.64, 95% CI
0.51–0.82; P \ 0.01).
Results of the entire cohort multivariate analysis for
DSS are similarly presented in Table 2A. Factors increas-
ing the risk of disease-related death included increasing age
(HR 1.01, 95% CI 1.00–1.02; P \ 0.001), carcinosarcoma
histology (HR 1.63, 95% CI 1.16–2.31, P = 0.005), T3
(HR 2.73, 95% CI 1.94–3.86; P \ 0.01) and T4 tumors
(HR 2.28, 95% CI 1.62–3.21; P \ 0.01), N1 status (HR
2.71, 95% CI 1.98–3.72; P \ 0.01), N2 status (HR 3.76,
95% CI 2.45–5.77; P \ 0.01), N3 status (HR 2.40, 95% CI
1.33–4.34; P \ 0.01), unknown nodal status (HR 2.24,
95% CI 1.58–3.20; P \ 0.01), and distant metastases (HR
5.32, 95% CI 3.80–7.45; P \ 0.01). Factors decreasing the
risk of disease-related death included T1 tumors (HR 0.59,
95% CI 0.39–0.88; P \ 0.01), lower grade (I/II) tumors
(HR 0.51, 95% CI 0.29–0.89; P = 0.02), and use of RT
(HR 0.74, 95% CI 0.56–0.96; P \ 0.03).
Multivariate analysis was repeated after stratifying
patients according to whether they received lumpectomy
(Table 2B) or mastectomy (Table 2C). The influence of RT
on OS and DSS in lumpectomy and mastectomy groups is
summarized in Table 3. Within the lumpectomy cohort, RT
was associated with an OS benefit (HR 0.51, 95% CI 0.32–
TABLE 1 Clinicopathologic characteristics; n = 1501
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0.79; P \ 0.01) but not a DSS benefit (HR 0.93, 95% CI
0.56–1.56; P = 0.93). Likewise, in the mastectomy cohort,
an OS benefit (HR 0.67, 95% CI 0.49–0.90; P \ 0.01) but
not a DSS benefit was associated with RT (HR 0.73, 95%
CI 0.52–1.02; P = 0.06).
Next, we evaluated whether or not there was a particular
group of patients undergoing mastectomy who selectively
garnered benefit from RT. Patients receiving mastectomy
were separated into two cohorts: ‘‘high risk’’ patients with
tumors larger than 5 cm in size or more than 4 metastatic
axillary lymph nodes (n = 338) and ‘‘normal risk’’ patients
with tumors smaller than 5 cm in size and fewer than 4
metastatic axillary lymph nodes (n = 438). Radiation
therapy was received by 39.3% (n = 133) of ‘‘high risk’’
patients and 12.3% (n = 54) of ‘‘normal risk’’ patients.
Multivariate analysis for ‘‘high risk’’ patients revealed RT
to be associated with both improved OS (HR 0.53, 95% CI
0.36–0.77; P \ 0.001) and DSS (HR 0.58, 95% CI 0.38–
0.88; P = 0.01). Multivariate analysis for ‘‘normal risk’’
patients, however, revealed no association between RT and
improved OS (HR 1.07, 95% CI 0.56–2.03; P = 0.83) or
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FIG. 2 a Overall survival—




























12096 192168144 2164824 72
b
Survival
FIG. 3 a Overall survival—
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TABLE 2 Multivariate analysis
Variable OS HR 95% CI/P value DSS HR 95% CI/P value
A: Entire cohort; n = 1501
Age 1.02 1.02–1.03; P \ .01 1.01 1.00–1.02; P \ .01
Ethnicity/race
Caucasian 1.00 (referent) 1.00 (referent)
Black 1.00 0.75–1.32; P = .99 1.00 0.73–1.38; P = .99
Asian/Pacific 0.72 0.45–1.13; P = .15 0.82 0.49–1.37; P = .44
Islander
Hispanic 1.45 0.96–2.21; P = .08 1.47 0.91–2.37; P = .88
Histologic subtype
Metaplastic NOS 1.00 (referent) 1.00 (referent)
Adenocartilaginous 1.49 0.87–2.55; P = .15 1.47 0.76–2.83; P = .25
Adenospindle 1.42 0.99–2.04; P = .06 1.24 0.77–1.99; P = .37
Adenosquamous 1.22 0.94–1.59; P = .13 1.27 0.94–1.74; P = .12
Carcinosarcoma 1.52 1.13–2.04; P = .005 1.63 1.16–2.31; P = .005
Epithelial 1.00 0.50–2.00; P = .99 1.00 0.40–2.49; P = .99
Myoepithelial 1.31 0.68–2.54; P = .42 1.33 0.53–3.34; P = .54
T stage
T2 1.00 (referent) 1.00 (referent)
T1 0.68 0.50–0.93; P = .02 0.59 0.39–0.88; P \ .01
T3 2.82 2.12–3.75; P \ .01 2.73 1.94–3.86; P \ .01
T4 1.95 1.45–2.61; P \ .01 2.28 1.62–3.21; P \ .01
N stage
N0 1.00 (referent) 1.00 (referent)
N1 2.40 1.83–3.15; P \ .01 2.71 1.98–3.72; P \ .01
N2 2.71 1.83–4.02; P \ .01 3.76 2.45–5.77; P \ .01
N3 1.92 1.11–3.33; P = .02 2.40 1.33–4.34; P \ .01
Unknown 2.32 1.76–3.06; P \ .01 2.24 1.58–3.20; P \ .01
M stage
M0 1.00 (referent) 1.00 (referent)
M1 4.73 3.51–6.39; P \ .01 5.32 3.80–7.45; P \ .01
Tumor grade
III/IV 1.00 (referent) 1.00 (referent)
I/II 0.72 0.48–1.06; P = .10 0.51 0.29–0.89; P = .02
Hormonal receptor status None significant None significant
Surgery type
Mastectomy 1.00 (referent) 1.00 (referent)
Lumpectomy 1.02 0.78–1.33; P = .91 1.20 0.87–1.64; P = .26
None 1.03 0.63–1.71; P = .90 1.19 0.66–2.16; P = .56
Radiation therapy
No 1.00 (referent) 1.00 (referent)
Yes 0.64 0.51–0.82; P \ .01 0.74 0.56–0.96; P \ .03
B: lumpectomy only; n = 615
Age 1.03 1.01-1.05; p \ 0.01 1.00 0.98-1.02; p = 0.89
Ethnicity/race
Caucasian 1.00 (referent) 1.00 (referent)
Black 1.32 0.66–2.64; P = .44 1.03 0.50–2.14; P = .93
Asian/Pacific 1.06 0.31–3.63; P = .93 1.05 0.36–3.04; P = .93
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TABLE 2 continued
Variable OS HR 95% CI/P value DSS HR 95% CI/P value
Islander
Hispanic 2.76 1.20–6.37; P = .02 1.08 0.38–3.04; P = .89
Histologic subtype
Metaplastic NOS 1.00 (referent) 1.00 (referent)
Adenocartilaginous 1.36 0.52–3.56; P = .53 1.02 0.38–2.75; P = .97
Adenospindle 1.07 0.55–2.11; P = .84 1.01 0.40–2.58; P = .98
Adenosquamous 1.85 1.03–3.31; P = .04 1.07 0.58–1.97; P = .83
Carcinosarcoma 1.46 0.14–2.90; P = .28 1.09 0.50–2.40; P = .82
Epithelial 0.52 0.14–1.91; P = .33 0.87 0.16–4.59; P = .87
Myoepithelial 2.25 0.80–6.31; P = .12 1.02 0.24–4.29; P = .98
T stage
T2 1.00 (referent) 1.00 (referent)
T1 0.64 0.39–1.04; P = .07 0.97 0.59–1.58; P = .89
T3 3.59 1.12–11.57; P = .03 1.13 0.22–5.92; P = .88
T4 1.37 0.66–2.88; P = .40 0.98 0.27–3.54; P = .98
N stage
N0 1.00 (referent) 1.00 (referent)
N1 2.61 1.29–5.25; P \ .01 1.17 0.55–2.50; P = .68
N2 11.68 4.74–28.73; P \ .01 1.75 0.37–8.35; P = .49
N3 18.18 6.74–49.06; P \ .01 2.10 0.29–15.42; P = .47
Unknown 2.86 1.68–4.89; P \ .01 1.12 0.56–2.24; P = .76
M stage
M0 1.00 (referent) 1.00 (referent)
M1 39.84 22.05–72.00; P \ .01 6.27 1.87–21.06; P \ .01
Tumor grade
III/IV 1.00 (referent) 1.00 (referent)
I/II 0.56 0.27–1.15; P = .12 0.91 0.44–1.88; P = .79
Hormonal receptor status None significant None significant
Radiation therapy
No 1.00 (referent) 1.00 (referent)
Yes 0.51 0.32–0.79; P \ .01 0.93 0.56–1.56; P = .79
C: mastectomy only; n = 833
Age 1.02 1.01–1.03; P \ .01 1.01 0.99–1.01; P = .14
Ethnicity/race
Caucasian 1.00 (referent) 1.00 (referent)
Black 1.04 0.75–1.45; P = .81 1.10 0.74–1.60; P = .66
Asian/Pacific 0.78 0.47–1.32; P = .36 0.86 0.46–1.59; P = .63
Islander
Hispanic 1.33 0.55–3.09; P = .39 1.50 0.79–2.69; P = .23
Histologic subtype
Metaplastic NOS 1.00 (referent) 1.00 (referent)
Adenocartilaginous 1.75 0.86–3.57; P = .12 1.75 0.69–4.45; P = .24
Adenospindle 1.56 0.99–2.46; P = .06 1.18 0.64–2.17; P = .59
Adenosquamous 1.00 0.71–1.40; P = .99 1.02 0.69–1.52; P = .91
Carcinosarcoma 1.35 0.95–1.91; P = .09 1.45 0.96–2.21; P = .08
Epithelial 0.95 0.37–2.42; P = .91 1.32 0.47–3.76; P = .60
Myoepithelial 0.68 0.21–2.21; P = .52 1.00 0.23–4.30; P = .99
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Multivariate analyses were repeated for each cohort
excluding patients with M1 disease (6.1%, n = 92).
Overall, for the entire cohort, the association between RT
and improved survival persisted for both OS (HR 0.62;
P B 0.001, 95% CI 0.48–0.81) and DSS (HR 0.66;
P B 0.01, 95% CI 0.49–0.90).
Era of treatment was not a significant factor predicting
OS or DSS (HR 1.16, 95% CI 0.85–1.59; P = 0.34 and HR
1.14, 95% CI 0.79–1.65; P = 0.48).
DISCUSSION
Other than a lower rate of lymph node metastases, MBC
tumors display poorer prognostic features relative to
IDC.8,11,14,15 This more aggressive prognostic profile
prompted us to examine if the use of adjuvant RT would
lead to improvements in OS and DSS.
Results of our multivariate analysis of the entire patient
cohort indicated that RT improved both OS and DSS.
Patients receiving RT demonstrated 36 and 26% decreases
in death from any cause and breast-related mortality,
respectively. Results of multivariate analyses excluding
patients with metastatic disease paralleled these findings,
demonstrating 38 and 34% decreases in death from any
cause and breast-related mortality, respectively.
We recognize heterogeneity in our study population. Just
over 40% of patients received lumpectomy for primary
surgical treatment, while more than 55% received mastec-
tomy. To ensure that the survival benefit attributed to the use
of RT was not due to the differential use of RT receiving one
type of surgery over another, we repeated our multivariate
analyses after stratifying patients according to their surgical
procedure. Indications for the use of RT are different for
patients receiving lumpectomy compared with mastectomy.
Postlumpectomy RT is a standard component of breast
conservation therapy for treating IDC to minimize local
recurrence.16 In our study, approximately 62% of lump-
ectomy patients received RT, suggesting the need for
TABLE 2 continued
Variable OS HR 95% CI/P value DSS HR 95% CI/P value
T stage
T2 1.00 (referent) 1.00 (referent)
T1 0.89 0.56–1.39; P = .60 0.56 0.29–1.11; P = .10
T3 2.96 2.13–4.11; P \ .01 2.95 1.97–4.40; P \ .01
T4 2.19 1.55–3.08; P \ .01 2.74 1.82–4.12; P \ .01
N stage
N0 1.00 (referent) 1.00 (referent)
N1 2.28 1.65–3.14; P \ .01 2.41 1.65–3.52; P \ .01
N2 2.44 1.56–3.81; P \ .01 3.14 1.92–5.15; P \ .01
N3 1.70 0.89–3.26; P = .11 1.87 0.92–3.79; P = .08
Unknown 2.47 1.72–3.55; P \ .01 12.12 1.31–3.45; P \ .01
M stage
M0 1.00 (referent) 1.00 (referent)
M1 4.15 2.89–5.97; P \ .01 4.25 2.82–6.40; P \ .01
Tumor grade
III/IV 1.00 (referent) 1.00 (referent)
I/II 0.82 0.49–1.36; P = .43 0.78 0.41–1.50; P = .46
Hormonal receptor status None significant None significant
Radiation therapy
No 1.00 (referent) 1.00 (referent)
Yes 0.67 0.49–0.90; P \ .01 0.73 0.52–1.02; P = .06
TABLE 3 Effect of radiation therapy on multivariate analysis among several surgical cohorts
Cohort OS HR 95% CI/P value DSS HR 95% CI/P value
Entire cohort 0.64 0.51–0.82; P \ .01 0.74 0.56–0.96; P \ .03
Lumpectomy only 0.51 0.32–0.79; P \ .01 0.93 0.56–1.56; P = .79
Mastectomy only 0.67 0.49–0.90; P \ .01 0.73 0.52–1.02; P = .06
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further education for both physicians and patients. Unlike
the NSABP B-06 trial, which did not find a survival
advantage for patients with IDC receiving postlumpectomy
RT, our study demonstrated that lumpectomy patients
receiving RT had a 49% decreased risk of death from any
cause mortality, reflecting the biological differences
between MBC and IDC. MBC may be in the spectrum of
basal-like breast cancers, which are commonly of higher
grade and display more rapid growth.17–20 MBC cells
express lower levels of estrogen and progesterone recep-
tors, HER-2/neu receptors and express higher levels of Ki-
67 and p-53 compared to IDC cell lines.9,21 Genomic
profiling has shown downregulation of DNA repair path-
ways including BRCA1 pathway, PTEN, and TOP2A.18,22
These findings may explain MBC’s lower incidence of
lymphatic spread, resistance to traditional chemotherapy
regimens, and sensitivity to external beam RT.
Postmastectomy RT is recommended to patients with 4
or more metastatic axillary nodes, gross extracapsular
nodal extension, large (C5 cm) primary tumors, and chest
wall invasion.23–25 In our study, roughly 25% of mastec-
tomy patients received RT. Mastectomy patients who
received RT demonstrated a 33% decreased risk of death
from all-cause mortality. Subgroup analysis of ‘‘high’’ and
‘‘normal’’ risk patients showed that those undergoing
mastectomy with tumors C5 cm or 4 or more metastatic
axillary lymph nodes derived a 47 and 42% decreased risk
of death from any cause and breast-related mortality,
respectively. Patients undergoing mastectomy with tumors
B5 cm and fewer than 4 metastatic axillary lymph nodes,
however, derived no benefit from RT. Our data suggest that
RT should be considered as a component of multimodality
therapy for MBC patients with these advanced features
undergoing mastectomy.
Pezzi et al. examined characteristics of patient present-
ing with MBC using the National Cancer Database and
concluded that, compared with patients with IDC, patients
with MBC presented with larger tumor size, less nodal
involvement, and less hormonal receptor postivity.8 Our
data largely support these findings. Our patients presented
with large tumors; the median size was 3 cm and more than
67% were T stage T2 or greater. Approximately 62% had
N0 disease, and approximately 70% of tumors were ER/PR
negative. Pezzi et al. reported N0 status for 78% of their
patients and negative hormone receptor status in 89–90%
of their patients. Discrepancies with our data are possibly
due to the fact that 15% of our patients had unknown nodal
status and approximately 18% had unknown hormone
receptor status. Our study was more inclusive than that of
Pezzi et al., who only analyzed tumors coded with ICD-0-3
codes 8575/3. Our study included tumors with more het-
erogeneous histologic diagnoses. In addition to the ICD-0-
3 code for metaplastic breast cancer, we included codes
representing the following histologic subtypes: metaplastic
carcinoma not otherwise specified, carcinosarcoma,
malignant myoepithelioma, adenosquamous carcinoma,
epithelial-myoepithelial, and adenocarcinoma with squa-
mous/cartilaginous and spindle cell metaplasia. These are
more in line with the histologic distinctions described by
Wargotz et al., who subcategorized MBC into 5 types: matrix
producing, spindle like, squamous with ductal origin,
metaplastic with osteoclastic giant cells, and carcinosar-
coma.2–6 In our analysis, carcinosarcoma was associated
with both poorer OS (HR 1.52, 95% CI 1.13–2.04; P =
0.005) and DSS (HR 1.63, 95% CI 1.16–2.31; P = 0.005) in
the multivariate analysis among all patients (Table 2A).
These poorer survivals, however, were not seen upon
subgroup analysis, although there was a trend toward sig-
nificance within the mastectomy-only multivariate analysis
for poorer OS (HR 1.35, 95% CI 0.95–1.91; P = 0.09) and
DSS (HR 1.45, 95% CI 0.96–2.21; P = 0.08). These find-
ings may reflect biological differences between the
nonepithelial sarcomatous element found in carcinosarcoma
compared with the nonepithelial components of the other
histological variants. It is possible that the number of cases of
carcinosarcoma is underestimated in our study. It is plausible
that the metaplastic NOS histologic subtype represents an
admixture of carcinosarcoma and other lower-grade histol-
ogies. This heterogeneity of histologic types within the
metaplastic NOS category may be responsible for the
observed absence of impact on survival reported for meta-
plastic NOS.
The entire cohort of patients was divided into 2 eras: era
I patients representing those diagnosed in 2000 or earlier
and era II representing those treated after 2000. No dif-
ferences in outcomes were found between the 2 groups,
suggesting that MBC and combined epithelial-mesenchy-
mal histologic diagnoses from before and after 2000 are
similar entities.
Our results should be interpreted with an understanding
of its limitations. We excluded cases of MBC prior to 1988
because prior to 1988, data fields were less complete. As is,
data completeness could have influenced our data. Most
notably, T stage was unknown for 3.9%, N stage for 15.3%,
tumor grade for 20.2%, estrogen receptor status for 17.8%,
and progesterone receptor status for 18.5%. Of these, only
T stage and N stage could potentially influence the decision
to use adjuvant RT, making the significance of this missing
data less likely. Furthermore, while we have good infor-
mation regarding the type of treatment patients received,
we do not have data on the appropriateness or adequacy of
that treatment for individual patients.26 Our current anal-
yses could not completely account for all biases that could
potentially select for healthier patients in the cohort
receiving RT. Furthermore, histopathology data from
SEER is not centrally reviewed. Histologic subtypes
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studied in the current analysis represent those reported by
the examining pathologists. We contend that our report
reflects real-world outcomes. Unlike single-institution-
based studies that are subject to referral bias, our study
represents what is occurring at all levels of healthcare
institutions and may be more generalizable. Additionally,
we do not know whether or not patients received adjuvant
medical therapy. Because of the high incidence of hormone
receptor negativity in MBC, hormonal therapy is unlikely
to influence survival. Previous studies have shown that 33–
86% of MBC patients receive chemotherapy and are twice
as likely to receive chemotherapy as matched controls with
IDC.8,11,27 These tumors are largely chemoresistant, how-
ever.27 A Mayo clinic report of 27 patients treated over
20 years showed that 33% received chemotherapy that
resulted in one partial response.11
Our data suggest that RT should be included in the
multimodality treatment for MBC patients undergoing
breast conservation surgery and those patients with tumors
C5 cm or greater than 4 metastatic axillary lymph nodes
undergoing mastectomy. Prospective studies, though nee-
ded, are unlikely to be done due to the rarity of MBC.
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